Get the Stockscreener App
6.76
3.29%
-0.23
After Hours:
6.80
0.04
+0.59%
Zura Bio Ltd stock is traded at $6.76, with a volume of 522.78K.
It is down -3.29% in the last 24 hours and up +19.22% over the past month.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
See More
Previous Close:
$6.99
Open:
$6.96
24h Volume:
522.78K
Relative Volume:
0.84
Market Cap:
$641.39M
Revenue:
-
Net Income/Loss:
$-65.10M
P/E Ratio:
-9.5521
EPS:
-0.7077
Net Cash Flow:
$-53.50M
1W Performance:
-0.15%
1M Performance:
+19.22%
6M Performance:
+207.27%
1Y Performance:
+445.16%
1-Day Range:
$6.47
$7.09
1-Week Range:
$6.32
$7.10
52-Week Range:
$0.97
$7.19
Zura Bio Ltd Stock (ZURA) Company Profile
Name
Zura Bio Ltd
Sector
Industry
Phone
858-247-0520
Address
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
6.76 | 663.22M | 0 | -65.10M | -53.50M | -0.7077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | Wedbush | Outperform |
| Nov-04-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| May-03-24 | Initiated | Piper Sandler | Overweight |
| Oct-10-23 | Initiated | Ladenburg Thalmann | Buy |
| Aug-25-23 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Guggenheim | Buy |
| Jun-14-23 | Initiated | Chardan Capital Markets | Buy |
| May-24-23 | Initiated | Raymond James | Strong Buy |
View All
Zura Bio Ltd Stock (ZURA) Latest News
Zura Bio launches Phase 2 TibuSURE trial in systemic sclerosis at Athens congress - Traders Union
Zura Bio presents Phase 2 systemic sclerosis trial design By Investing.com - Investing.com India
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress - Yahoo Finance Singapore
Major Zura Bio (ZURA) holder acquires 2M shares in registered deal - Stock Titan
Access Industries group lifts Zura Bio (ZURA) stake to 18.2% - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Zura Bio heads to Miami for March 10-11 investor conferences - Stock Titan
Zura Bio raises $144 million in public offering of shares By Investing.com - Investing.com South Africa
Zura Bio raises $144 million in public offering of shares - Investing.com India
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - ChartMill
ZURA Should I Buy - Intellectia AI
Zura Bio (ZURA) revises Ogier legal opinion and consent in 8-K/A - Stock Titan
Zura Bio prices $125M public offering at $6.25 per share - Investing.com Australia
Zura Bio (ZURA) launches $6.25 share and pre-funded warrant sale - Stock Titan
Zura Bio (NASDAQ: ZURA) seeks roughly $117M from 18.2M-share offering - Stock Titan
Zura Bio Prices Public Offering of 18.2 Million Shares - Intellectia AI
Zura Bio prices $125M public offering at $6.25 per share By Investing.com - Investing.com South Africa
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - ChartMill
Director Mark Eisner files initial Form 3 for Zura Bio Ltd (ZURA) - Stock Titan
Zura Bio launches public offering of Class A shares By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - Stock Titan
Zura Bio adds two immunology executives to board By Investing.com - Investing.com India
Zura Bio adds two immunology executives to board - Investing.com Australia
Zura Bio (ZURA) appoints Mark Eisner and Ajay Nirula to its board - Stock Titan
Leaders behind four approved immunology drugs join Zura Bio board - Stock Titan
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors - Yahoo Finance
Risk Recap: What makes Zura Bio Limited stock attractive todayMarket Sentiment Report & Community Consensus Picks - baoquankhu1.vn
What risks investors should watch in Zura Bio Limited stockGDP Growth & Weekly High Momentum Picks - mfd.ru
Great Point discloses 3.8M Zura Bio (ZURA) shares in 13G/A - Stock Titan
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026 - Yahoo Finance
Why retail investors favor Zura Bio Limited stockWeekly Stock Recap & Daily Momentum Trading Reports - mfd.ru
ZURA PE Ratio & Valuation, Is ZURA Overvalued - Intellectia AI
Zura Bio Advances Tibulizumab Strategy in Autoimmune Diseases - TipRanks
Zura Bio Ltd Provides Updated Corporate Presentation - TradingView
This Nokia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Wedbush initiates coverage on Zura Bio stock with Outperform rating By Investing.com - Investing.com India
Wedbush initiates coverage on Zura Bio stock with Outperform rating - Investing.com
Wedbush Initiates Zura Bio at Outperform With $15 Price Target - marketscreener.com
Investment Report: Will Zura Bio Limited benefit from rising consumer demand2025 Short Interest & AI Driven Price Predictions - baoquankhu1.vn
Aug Update: Will Zura Bio Limited benefit from rising consumer demandJuly 2025 Chart Watch & Safe Capital Allocation Plans - baoquankhu1.vn
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit - ChartMill
Watch Zura Bio's Guggenheim biotech summit fireside chat live online - Stock Titan
Aug Sectors: What makes Zura Bio Limited stock attractive todayTrade Risk Assessment & Capital Protection Trading Alerts - baoquankhu1.vn
Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Pre-market volume spike for 94E.F Zura Bio (XETRA) 28 Jan 2026: watch EUR 5.20 level - Meyka
Zura Bio (NASDAQ:ZURA) Trading Up 0.3%What's Next? - MarketBeat
Zura Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Parvinder Thiara - Longbridge
Zura Bio Ltd Announces CEO Transition and Board Appointment - TradingView
Does Zura Bio Limited have pricing power2025 Technical Overview & Weekly Consistent Profit Watchlists - mfd.ru
CEO shake-up at Zura Bio (NASDAQ: ZURA) with new director added - Stock Titan
Zura Bio Ltd Stock (ZURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):